Key result
Activated coagulation markers show no link to infarct volume or 90-day ischemic stroke outcomes.
Why the study?
Are activated coagulation markers associated with final infarct volume and clinical outcomes in acute ischemic stroke patients, and is this effect modified by intravenous thrombolysis?
Cohort (n=116)
Are activated coagulation markers associated with final infarct volume and clinical outcomes in acute ischemic stroke patients, and is this effect modified by intravenous thrombolysis?
Answers are grounded in this paper and cite their sources.
Activated coagulation markers increase temporarily after IVT+EVT but are not significantly associated with final infarct volume or 90-day clinical outcomes in acute ischemic stroke patients.
Abstract Background The MR CLEAN NO-IV trial showed neither superiority nor noninferiority of endovascular treatment (EVT) alone compared to intravenous thrombolysis (IVT; Alteplase) before EVT in acute ischemic stroke (AIS) patients with large vessel occlusion of the anterior circulation. Although the treatment effect is largely attributable to EVT, IVT may affect hypercoagulability during AIS. Aims To investigate the association between activated coagulation and final infarct volume and clinical outcomes (modified Rankin Scale 3–6 and mortality 90 days post-EVT), and whether this effect is modified by IVT administration. Methods Enzyme-linked immunosorbent assays were used to quantify activated coagulation markers (activated coagulation factor (F) XIIa-C1 esterase inhibitor (C1inh); FXIIa-antithrombin (AT), FXIa-C1inh, FXIa-AT, FIXa-AT, FXa-AT, T-AT, FVIIa-AT) in plasma samples obtained on admission (T₀), 1 h post-EVT (T₁) and 24 h post-EVT (T₂). Multivariable regressions were performed to investigate the associations and effect modification. Results In the total cohort of 116 patients, a significant increase at T₁ was seen in FIXa-AT (p = .001), FXa-AT (p < .001), T-AT (p < .001), and FVIIa-AT (p = .012), while there was a significant increase at T₂ in FXIIa-C1inh (p < .001). Similar results were seen in the IVT+EVT subgroup. The EVT alone subgroup showed a significant temporary increase at T₁ in FXa-AT (p < .001) and T-AT (p = .014). Neither the enzyme:inhibitor complexes nor the interaction with IVT were significantly associated with the outcome measures. Conclusion Despite temporary significant increases in enzyme:inhibitor complexes in the IVT+EVT group, but not in the EVT alone group, there were no significant associations with final infarct volume and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Ceulemans et al. (2024) conducted a cohort in Acute ischemic stroke with large vessel occlusion of the anterior circulation (n=116). Activated coagulation markers was evaluated on Final infarct volume and clinical outcomes (modified Rankin Scale 3-6 and mortality at 90 days). Activated coagulation markers were not significantly associated with final infarct volume or 90-day clinical outcomes in acute ischemic stroke patients, regardless of IVT administration.
Synapse has enriched 10 related papers. Consider them for comparative context: